Is Retatrutide Approved? No — FDA Phase 3 Status

What Is Retatrutide’s FDA Approval Status in 2026?

As of April 15, 2026, retatrutide (LY-3437943) remains in Phase 3 without FDA approval, EMA approval, or clearance from any other regulator. Lilly has not filed a New Drug Application with the FDA, and there is no approved pharmacy or prescription pathway for retatrutide. Today the molecule remains investigational and legally tied to clinical-trial settings rather than commercial prescribing.

The first two public Phase 3 readouts came from TRIUMPH-4 on December 11, 2025 and TRANSCEND-T2D-1 on March 19, 2026. Those results strengthen the evidence base, but they do not change the current regulatory status: retatrutide remains in Phase 3 and still awaits any future filing package from Lilly.

Why Is Retatrutide Still in Phase 3?

FDA approval of any obesity medicine requires a completed registrational package, not a single standout result. Retatrutide’s Phase 3 development is still in the data-accumulation stage: two positive readouts are public, additional program results are still pending, and Lilly has not yet moved the molecule into a public NDA review cycle. Until those steps happen, approval remains a future possibility rather than a present status.

Lilly’s March 19, 2026 release on TRANSCEND-T2D-1 explicitly said additional results from the retatrutide clinical trial program are expected over the next year. That is the practical Phase 3 signal right now: active late-stage development is continuing, and the approval clock cannot start until Lilly turns that broader dataset into a formal filing.

When Could Lilly File a Retatrutide NDA?

There is still no announced NDA filing date for retatrutide. The current NDA watch is therefore about milestones rather than calendar promises: more late-stage readouts, clearer Lilly guidance on the sequence of indications, and a public statement that a submission has been made. Lilly still needs a broader late-stage package before filing, and until the company gives a formal filing signal, any month-by-month approval forecast is still speculative.

For users trying to separate status intent from device or dose intent: this page owns the approval question. If you actually need retatrutide dose math, exact mg-to-click conversions, 30mg pen hardware details, or the Phase 3 titration schedule, use those pages directly.

What Are the TRIUMPH Phase 3 Results So Far?

As of April 2026, two Phase 3 trials have reported positive results. TRIUMPH-4 (obesity + knee osteoarthritis) was announced December 11, 2025,^[1] and TRANSCEND-T2D-1 (type 2 diabetes) was announced March 19, 2026. Additional TRIUMPH readouts are expected over the coming year. As with many clinical trials, participants may not be guaranteed to receive the actual medication, as the study design is randomized and may include a placebo group. The safety and efficacy of retatrutide are still being evaluated in these ongoing clinical trials.

TRIUMPH-4 Efficacy Data

The headline: 28.7% mean body weight loss at the 12 mg dose — the highest weight-loss figure ever reported in a Phase 3 obesity trial.^[1] Participants on 12 mg lost an average of 71.2 lbs (32.3 kg). The placebo group achieved approximately 2–3% body weight reduction, underscoring the drug’s efficacy. Participants in clinical trials for retatrutide may not be guaranteed to receive the active drug, as many trials are randomized and blinded against a placebo group.

Beyond weight, TRIUMPH-4 was the first obesity drug trial to demonstrate significant improvement in osteoarthritis pain, with WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain scores reduced by 4.5 points (75.8% improvement). This positions retatrutide not just as a weight loss drug but as a potential treatment for obesity-related health conditions that affect patients’ physical activity and well-being.

TRANSCEND-T2D-1: Phase 3 Diabetes Data (March 2026)

On March 19, 2026, Eli Lilly announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 trial evaluating retatrutide in type 2 diabetes. The 40-week, placebo-controlled study randomized 537 participants to retatrutide 4 mg, 9 mg, or 12 mg (starting at 2 mg with 4-week dose escalation). Retatrutide met all primary and key secondary endpoints: A1C reductions of 1.7% to 2.0% across doses (vs. 0.8% placebo), and weight loss of 11.5% to 16.8% (12 mg = 36.6 lbs). GI adverse events were consistent with the incretin class: nausea (16.4–26.5%), diarrhea (18.7–26.3%), and vomiting (15.0–17.6%). Dysesthesia occurred in 2.3–4.5% of retatrutide-treated participants. Discontinuation rates due to adverse events were low (2.2–5.1%). Detailed results will be presented at the American Diabetes Association Scientific Sessions in June 2026.

Remaining Readouts

Lilly said on March 19, 2026 that additional results from the retatrutide clinical trial program are expected over the next year. That is the current filing watch: more late-stage readouts, more clarity on the broader registrational package, and then any eventual NDA announcement. Track the moving timeline on our TRIUMPH trial tracker and compare it with the wider 2026 approval tracker.

TRIUMPH-4: Knee Osteoarthritis Outcomes

TRIUMPH-4 was the first Phase 3 obesity drug trial to specifically enroll participants with knee osteoarthritis, and the results demonstrate how substantial weight loss translates directly to joint-level benefit. The data support two distinct therapeutic pathways: mechanical unloading and systemic anti-inflammatory effects.

Mechanical Unloading

Each kilogram of body weight lost reduces the compressive force on the knee joint by approximately 4 kg per step during walking. In a 115 kg individual achieving the trial’s 28.7% mean weight loss (~33 kg reduction), this translates to roughly 132 kg less compressive force per step. Over 6,000–8,000 daily steps, the cumulative reduction in joint loading is enormous — directly slowing cartilage wear and reducing the mechanical stimulus for pain.

Anti-Inflammatory Effects

Independent of weight loss, GLP-1 receptor agonists have demonstrated anti-inflammatory properties in preclinical studies. GLP-1 receptors are expressed in immune cells and synovial tissue. Activation reduces NF-κB signaling — a key pathway in inflammatory cytokine production. The dramatic reduction in adipose tissue also directly lowers circulating levels of IL-6, TNF-α, and adipokines that contribute to synovial inflammation and cartilage matrix degradation. The glucagon receptor component further amplifies fat mass reduction through increased energy expenditure, potentially enhancing this anti-inflammatory benefit beyond what GLP-1-only drugs achieve.

The approximately 8–9 percentage points of additional weight loss with retatrutide versus tirzepatide in their respective knee OA trials is notable, though direct cross-trial comparisons are limited by differences in study design, populations, and endpoints. For the full TRIUMPH-4 knee OA analysis, see our dedicated retatrutide and knee osteoarthritis article.

Limitations

Structural outcomes: Pain relief does not necessarily mean cartilage preservation. Whether retatrutide-induced weight loss slows radiographic progression of knee OA (joint space narrowing, osteophyte formation) is not addressed by the available data.

Durability: Knee OA pain improvement during active weight-loss treatment may not persist if weight is regained after discontinuation. TRIUMPH-6 (weight maintenance) will provide relevant durability data.

Generalizability: TRIUMPH-4 enrolled participants with both obesity and knee OA. Whether the joint benefits extend to other weight-bearing joints (hip, ankle) or lower BMI ranges is unknown.

What About the Dysesthesia Safety Signal?

In TRIUMPH-4, approximately 20.9% of patients on the highest retatrutide dose reported dysesthesia — a skin sensitivity phenomenon described as tingling, tenderness, or altered sensation. This was higher than the rate seen in Phase 2 and is the most notable non-GI safety signal to emerge from the program so far.

Dysesthesia is not life-threatening and was generally described as mild to moderate in severity. However, the rate is clinically meaningful and distinguishes retatrutide from other GLP-1-class drugs, which do not typically produce this side effect. Eli Lilly has stated that the signal is being monitored across all ongoing TRIUMPH trials.

Whether dysesthesia affects regulatory review or labeling remains to be seen. The FDA will weigh this signal against the overall benefit-risk profile when the NDA is eventually submitted.

For dose-by-dose GI rates, discontinuation data, and a full adverse event breakdown, see our retatrutide side effects guide.

Adverse Events in Retatrutide Trials

Across Phase 2 and Phase 3 clinical trials, the most frequently reported adverse events with retatrutide have been gastrointestinal in nature. Nausea, diarrhea, vomiting, and constipation were the leading symptoms, consistent with the known side-effect profile of GLP-1 drugs and other incretin-based medications. These adverse events generally peaked during the dose-titration period and diminished as patients continued treatment at higher doses.

Retatrutide’s mechanism of action includes delaying gastric emptying, reducing appetite, and ultimately decreasing food intake, which contributes to its weight loss effects. At the 12 mg dose in TRIUMPH-4, nausea and vomiting rates were comparable to those seen with other weight loss drugs such as semaglutide and tirzepatide. When compared to semaglutide and tirzepatide, retatrutide shows similar efficacy and a comparable side effect profile, particularly regarding gastrointestinal symptoms. Decreased appetite — a pharmacological effect of the GLP-1 and GIP hormones that retatrutide activates — was commonly reported but is generally considered a therapeutic mechanism rather than an adverse event. Discontinuation rates due to adverse events remained low, suggesting the drug’s risks are manageable for most patients treated in clinical trials.

It is important to note that retatrutide cannot be used in compounded medicines under federal law, as it is not an FDA-approved drug. A healthy diet and physical activity were recommended alongside retatrutide in all TRIUMPH protocols, which is standard practice for obesity medicine clinical trials. Before enrolling in a clinical trial for retatrutide, individuals go through an informed consent process to understand the risks and benefits. Full side-effect data by dose is available in our retatrutide side effects guide.

When Could Retatrutide Be Approved?

No approval date has been confirmed. Based on publicly available information, the sequence still looks like this:

2026: more late-stage data. Two Phase 3 readouts are already public (TRIUMPH-4 and TRANSCEND-T2D-1), and Lilly said on March 19, 2026 that additional results from the retatrutide clinical trial program are expected over the next year. Lilly still needs a broader late-stage package before filing.

Next milestone: future NDA filing. Lilly still needs a broader Phase 3 package before filing, and as of April 15, 2026 the company has not publicly announced an NDA filing date.

After filing: FDA review and decision. Only once Lilly submits an NDA can a credible approval window be estimated. Standard review timelines matter, but they start from an actual filing date rather than investor-side projections. Track all upcoming decisions on the obesity drug approval tracker.

Can You Get a Retatrutide Prescription?

No. Because retatrutide is not an approved drug, it cannot be prescribed by a doctor or dispensed by any pharmacy. There is no prescription pathway, no off-label prescribing option, and no legitimate online pharmacy that carries this medicine. Individuals interested in access to retatrutide must participate in a clinical trial to receive the medication, as retatrutide is only legally available through participation in Eli Lilly’s clinical trials. Keep the distinction clear: research-only supply is not the same as a regulatory approval or prescription pathway.

Concerns About Illegal Sales

The FDA has issued warnings against the illegal sale of retatrutide and other GLP-1 drugs online. Any products claiming to be retatrutide outside of clinical trials are not legitimate and are illegal. Regulations are in place to protect consumers from illegitimate products and to safeguard the integrity of the supply chain by preventing substandard APIs from entering the market. Patients who buy unapproved medications from unregulated sources face serious health concerns: products may be contaminated, mislabeled, or contain no active ingredient at all. For a country-by-country breakdown of what is and isn’t permitted, see our peptide legality guide. Unlike approved alternatives such as semaglutide or tirzepatide, retatrutide has no verified pharmaceutical supply chain and no regulatory oversight outside of Eli Lilly’s controlled trial environment.

How to Find Retatrutide Clinical Trials

To find clinical trials for retatrutide, individuals can search on ClinicalTrials.gov, which is a government-run website listing human clinical trials for investigational medications like retatrutide. Use the search term “retatrutide” or “LY-3437943.” Enrollment status varies by study and site, and several late-stage programs continue beyond 2026. Discuss eligibility with your healthcare provider to determine whether a retatrutide trial is an appropriate option for your research or care context.

What Is Retatrutide?

Retatrutide (LY-3437943) is an investigational once-weekly injectable drug developed by Eli Lilly that simultaneously activates three gut hormones: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. It is the first drug targeting all three of these hormones to reach Phase 3 clinical trials for the treatment of obesity. For a detailed breakdown of each receptor’s contribution, see our triple-agonist pathway analysis.

How Retatrutide Differs from Other Weight Loss Medications

The three-hormone mechanism is the key differentiator. Currently approved medications for weight management include semaglutide (Wegovy) and tirzepatide (Zepbound), which target one or two of these hormones. Retatrutide adds glucagon receptor activation on top of the GLP-1 and GIP pathways used by tirzepatide. When compared to existing GLP-1 medications, retatrutide’s triple action may lead to greater weight loss and improved metabolic health. For a head-to-head comparison with these alternatives, see Retatrutide vs Tirzepatide vs CagriSema. Glucagon receptor signaling increases energy expenditure, promotes hepatic fat oxidation, and enhances lipid metabolism — pathways that may explain why patients on retatrutide lose more weight than those on existing drugs. Several other pharmaceutical companies are also developing multi-receptor obesity medicines, including Novo Nordisk’s amylin-based petrelintide and zenagamtide, as well as CagriSema — but retatrutide is the furthest along in clinical development.

In the Phase 2 trial published in the New England Journal of Medicine in 2023, the 12 mg dose produced 24.2% mean body weight loss at 48 weeks — at the time, the highest weight loss ever reported for any anti-obesity drug. The Phase 3 TRIUMPH-4 result (28.7% at 68 weeks) extended that lead further, establishing retatrutide as the most effective investigational medicine for treating obesity in terms of weight reduction. For the Phase 3 titration schedule, see our retatrutide dosage guide. For exact mg-to-click lookup, use the retatrutide clicks guide. For ongoing study coverage, use the TRIUMPH trial tracker and the 2026 approval tracker.